Baxter International Inc. BAX

Baxter International Inc., a través de sus subsidiarias, ofrece una cartera de productos de atención médica esenciales. Los productos de la compañía incluyen cuidado renal, entrega de medicamentos, productos farmacéuticos, nutrición clínica, cirugía avanzada y terapias agudas. Su oferta de cuidado renal incluye diálisis peritoneal (DP), hemodiálisis (HD) y terapias y servicios adicionales de diálisis. Sus ofertas de entrega de medicamentos incluyen terapias intravenosas (IV), bombas de infusión, juegos de administración y dispositivos de reconstitución de medicamentos. Sus ofertas farmacéuticas incluyen plataformas de medicamentos premix y oncológicos, anestesia inhalada y productos de cuidados críticos y servicios de compuestos farmacéuticos. Sus ofertas de nutrición clínica incluyen terapias de nutrición parenteral (PN) y productos relacionados. Sus ofertas de cirugía avanzada incluyen productos biológicos y dispositivos médicos utilizados en procedimientos quirúrgicos para hemostasia, sellado de tejidos y prevención de adherencias. También ofrece productos del sistema hemostático de polisacáridos (PerClot).

Con 41 acciones de BAX (USD 988,51) habrías recibido USD 1,64 en dividendos en los últimos 12 meses.

• Zacks Investment Research 29 sept

  Why Investors Need to Take Advantage of These 2 Medical Stocks Now

  The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat quarterly earnings estimates by comparing the most recent analyst estimates against consensus estimates. When combined with a Zacks Rank of #3 or better, stocks with positive ESP have historically produced 70% positive surprises and 28.3% average annual returns. The article highlights Eli Lilly and Baxter International as examples of stocks with positive ESP ahead of their October 29, 2026 earnings releases.

  

• GlobeNewswire Inc. 24 sept

  Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGR

  The global veterinary ophthalmology equipment market is expected to grow from USD 0.57 billion in 2026 to USD 0.83 billion by 2031, at a 7.7% CAGR. Growth is driven by rising pet ownership, increased prevalence of animal eye diseases, and adoption of advanced diagnostic and surgical technologies. Treatment applications and surgical equipment segments are leading growth, with Asia Pacific emerging as the fastest-growing region.

  

• GlobeNewswire Inc. 9 sept

  Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

  The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

  

• GlobeNewswire Inc. 7 sept

  Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

  The global drug reconstitution systems market is expected to grow at a 7.0% CAGR from $5.9 billion in 2026 to $10.8 billion by 2035, driven by expanding biologic and biosimilar pipelines, increasing demand for safer drug delivery systems, and the shift toward home healthcare and self-administered therapies. Cartridges lead the market at 50% revenue share, while prefilled syringes are expected to grow faster. Asia-Pacific is projected to achieve the fastest regional growth.

  

• The Motley Fool 31 jul

  Why Baxter International Stock Skyrocketed by 19% This Week

  Baxter International's stock surged 19% following strong second-quarter earnings that beat analyst expectations. The company reported $2.96 billion in sales (5% YoY growth) and raised full-year guidance for both revenue growth (3-4%) and adjusted EPS ($1.95-$2.15), citing strong performance across both product categories and geographic regions.